{
    "body": "Name monoclonal antibody against SLAMF7.", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26035255", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25287778", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25312647", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24941981"
    ], 
    "ideal_answer": [
        "Elotuzumab is a humanized monoclonal antibody specific for signaling lymphocytic activation molecule-F7 (SLAMF7, also known as CS1, CD319, or CRACC) that enhances natural killer cell-mediated antibody-dependent cellular cytotoxicity of SLAMF7-expressing myeloma cells."
    ], 
    "exact_answer": [
        "signaling lymphocytic activation molecule-F7"
    ], 
    "concepts": [
        "http://www.uniprot.org/uniprot/SLAF7_HUMAN", 
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000911"
    ], 
    "type": "factoid", 
    "id": "56c077e9ef6e394741000021", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 276, 
            "text": "BACKGROUND: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26035255", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 280, 
            "text": "Elotuzumab is a humanized monoclonal antibody specific for signaling lymphocytic activation molecule-F7 (SLAMF7, also known as CS1, CD319, or CRACC) that enhances natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) of SLAMF7-expressing myeloma cells.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25287778", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 183, 
            "offsetInEndSection": 275, 
            "text": "This led to development of an anti-SLAMF7 antibody, elotuzumab, showing efficacy against MM.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25312647", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 165, 
            "offsetInEndSection": 347, 
            "text": "One of the most promising MoAb is elotuzumab, the only humanized IgG1 MoAb specifically targeting CS1 (SLAMF7), a cell surface glycoprotein that is highly expressed in plasma cells. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24941981", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 273, 
            "offsetInEndSection": 365, 
            "text": "This led to development of an anti-SLAMF7 antibody, elotuzumab, showing efficacy against MM.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25312647", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 281, 
            "text": "Elotuzumab is a humanized monoclonal antibody specific for signaling lymphocytic activation molecule-F7 (SLAMF7, also known as CS1, CD319, or CRACC) that enhances natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) of SLAMF7-expressing myeloma cells.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25287778", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 347, 
            "text": " New agents are awaited for the treatment of multiple myeloma and research is ongoing for the development of monoclonal antibodies (MoAbs) targeting the tumor cells. One of the most promising MoAb is elotuzumab, the only humanized IgG1 MoAb specifically targeting CS1 (SLAMF7), a cell surface glycoprotein that is highly expressed in plasma cells.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24941981", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 184, 
            "offsetInEndSection": 276, 
            "text": "This led to development of an anti-SLAMF7 antibody, elotuzumab, showing efficacy against MM.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25312647", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 265, 
            "text": "Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26035255", 
            "endSection": "abstract"
        }
    ]
}